Strategies to identify patients for antihypertensive treatment
Elevated blood pressure is the major risk factor for disease and premature death globally, and the association between blood pressure and fatal cardiovascular complications is strong.
1,2 Antihypertensive treatment can reduce cardiovascular morbidity and all-cause mortality and, supported by evidence summarised in 2018, 3 lower target blood pressure values have been introduced into existing recommendations on the management of hypertension. 4, 5 However, the absolute benefit of antihypertensive treatment in reducing cardiovascular events is determined by the overall cardiovascular risk of the individual. Therefore, a strategy to identify patients to be offered antihypertensive treatment based on cardiovascular risk might be superior to a strategy that offers treatment on the basis of threshold blood pressure values alone.
In The Lancet, Emily Herrett and colleagues 6 report on the eligibility and outcomes of offering antihypertensive treatment on the basis of cardiovascular risk compared with those of strategies relying on blood pressure level. This retrospective cohort study in the UK collected information from primary care, diagnoses, and procedures from hospital-based care, and mortality data for 1 222 670 people (57% women) aged 30-79 years with no previous cardiovascular disease. Herrett and colleagues compared four strategies to define treatment eligibility: a blood pressure of 140/90 mm Hg or higher alone, existing (2011) and proposed (2019) UK National Institute for Health and Care Excellence (NICE) guidelines on the management of hypertension, and an absolute risk strategy based on a predicted 10-year cardiovascular event risk (according to QRISK2) of 10% or greater. The primary outcome was a first cardiovascular diagnosis of coronary artery disease or cerebrovascular disease. Median age at entry was 51 years (IQR 41-62), blood pressure was 129/78 mm Hg, and 18% of participants were on antihypertensive treatment. During a median follow-up of 4·3 years (IQR 2·5-5·2), 7·1 cardiovascular events per 1000 person-years were diagnosed.
The proportion of patients eligible for treatment was higher with a strategy based on blood pressure alone (39·4%) than with strategies based on NICE 2011 (22·2%) and NICE 2019 (26·8%) guidelines or with a risk-based strategy alone (29·3%). More importantly, however, the efficiencies of the strategies were different: cardiovascular event rates in patients eligible for treatment with each strategy were 11·4 per 1000 person-years (95% CI 11·3-11·6) with a blood pressure strategy, 15·2 (15·0-15·5) with NICE 2011 guidelines, 14·9 (14·7-15·1) with NICE 2019 guidelines, and 16·9 (16·7-17·1) with a risk-based strategy. Therefore, a strategy based on blood pressure alone would require 38 patients treated for 10 years to avoid one event. Treatment based on NICE 2011 guidelines would require 28 and NICE 2019 guidelines 29 treated patients, whereas an absolute risk strategy would require 27 patients treated for 10 years to avoid one event. Therefore, these results suggest that, with a similar efficiency, a strategy based on absolute risk would prevent substantially more people from incident cardiovascular disease than strategies based on NICE 2011 or NICE 2019 guidelines.
Herrett and colleagues' results add evidence favouring a strategy where offering antihypertensive treatment on the basis of cardiovascular risk might be superior to treating people on the basis of blood pressure values alone. 7, 8 Nevertheless, we should always recommend lifestyle modifications and consider drug treatment (when appropriate) for dyslipidaemia and glucose intolerance, as well as support smoking cessation to reduce cardiovascular risk. Notably, only 43-70% of the patients eligible for treatment under any of the four strategies received antihypertensive treatment, and only half of those treated achieved blood pressure lower than 140/90 mm Hg. Therefore, and corroborating the findings of other studies, 4, 5 adherence by care providers to guideline recommendations to treat blood pressure to target levels needs to be improved, along with treatment strategies based on cardiovascular risk.
Some limitations of Herrett and colleagues' study should be considered. First, a target blood pressure of 130/80 mm Hg or lower in patients aged 65 years or younger is recommended, but the additional benefits of a blood pressure lower than 120/70 mm Hg is less certain and might associate with an increased cardiovascular risk. 4, 5 Furthermore, the evidence supporting a reduction in cardiovascular events by starting antihypertensive treatment at blood pressure values lower than 140/90 mm Hg is unclear, particularly in people without high cardiovascular risk and in older individuals. 4, 5 A risk-based strategy would also make people with normal or slightly elevated blood pressure eligible for antihypertensive treatment. Second, the prevalence of hypertension increases sharply with age, and the number of old and very old people treated for hypertension is high. 9 Additionally, among treated patients with hypertension aged 90 years or older, a third of women and a fourth of men are free of cardiovascular comorbidity, diabetes, or chronic obstructive pulmonary disease. 9 However, Herrett and colleagues did not investigate people aged 80 years or older, in whom the possible benefits or harms of a risk-based treatment strategy remain to be assessed. Third, the study used QRISK2 10 for the strategy based on cardiovascular risk. Other recommended risk score systems used in Europe, such as the Systematic Coronary Risk Evaluation (SCORE) 11 and the SCORE OP (older persons), 12 use less background information, calculate a 10-year cardiovascular mortality risk, or both. The use of these risk scores might not yield results similar to those of this study. However, Herrett and colleagues' findings of antihypertensive treatment eligibility based on cardiovascular risk being superior to eligibility based on blood pressure alone would most likely persist.
In conclusion, the work of Herrett and colleagues shows the importance of assessing cardiovascular risk in the management of hypertension, and suggests that a strategy to offer antihypertensive therapy based on absolute cardiovascular risk might prevent more cardiovascular disease than a strategy based on blood pressure alone. 
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